论文部分内容阅读
目的探讨反义Stathmin基因的核酸(antisense of stathmin ologodeoxynucleotides,ASODN)对人胃癌细胞系生长的影响及对裸鼠体内肿瘤生长的作用。方法免疫组化检测2010-01-2013-06山东省千佛山医院40例胃癌标本中癌组织及癌旁组织中Stathmin的表达;以人胃癌MCG803细胞系为靶细胞,分为ASODN转染细胞组、SODN转染组及未转染组3组,ASODN为阻断剂,观察ASODN对胃癌细胞的增殖的影响;40只腹腔种植胃癌细胞的裸鼠随机分为2组,观察转染ASODN在裸鼠体内对肿瘤生长的影响。结果Stathmin在胃癌组织中的阳性表达率为77.5%(32/40),显著高于癌旁组织的32.5%(13/40),差异有统计学意义,P<0.001;未转染组及SODN转染组胃癌细胞倍增时间(20h)明显短于ASODN转染组(27h);随时间进展,ASODN转染组细胞增殖能力均受抑制,差异有统计学意义,P<0.001;转染ASODN胃癌细胞裸鼠的肿瘤组织体积平为(2.98±0.12)mm3,小于未转染ASODN组肿瘤组织(7.61±0.21)mm3,P=0.036。结论 ASODN对胃癌细胞的生长有抑制的作用,有望成为胃癌治疗的新靶点,以提高胃癌患者的生存时间。
Objective To investigate the effect of antisense of stathmin genes (ASODN) on the growth of human gastric cancer cell lines and the effect on tumor growth in nude mice. Methods Immunohistochemistry was used to detect the expression of Stathmin in 40 cases of gastric cancer specimens from the Qianfoshan Hospital of Shandong Province from January 2010 to June 2013. The human gastric cancer MCG803 cells were used as the target cells and divided into ASODN transfected group , SODN transfection group and untransfected group. ASODN was used as a blocker to observe the effect of ASODN on the proliferation of gastric cancer cells. Forty peritoneal gastric cancer cell lines were randomly divided into 2 groups. Effects of Tumor Growth in Mice. Results The positive rate of Stathmin in gastric cancer tissues was 77.5% (32/40), which was significantly higher than that in adjacent tissues (32.5%, 13/40), with statistical significance The doubling time (20h) in transfected gastric cancer cells was significantly shorter than that in ASODN transfected cells (27h). With the progression of time, the proliferation of ASODN transfected cells was inhibited, the difference was statistically significant, P <0.001; The tumor volume of the nude mice was (2.98 ± 0.12) mm3, which was less than that of the untransfected ASODN tumor (7.61 ± 0.21) mm3, P = 0.036. Conclusions ASODN can inhibit the growth of gastric cancer cells and is expected to become a new target of gastric cancer therapy in order to improve the survival time of gastric cancer patients.